1. Exposure‐response relationship of ramucirumab in RANGE, a randomized phase III trial in advanced urothelial carcinoma refractory to platinum therapy. Issue 7 (7th February 2022) Authors: de Wit, Ronald; Powles, Thomas; Castellano, Daniel; Necchi, Andrea; Lee, Jae‐Lyun; van der Heijden, Michiel S.; Matsubara, Nobuaki; Bamias, Aristotelis; Fléchon, Aude; Sternberg, Cora N.; Drakaki, Alexandra; Yu, Evan Y.; Zimmermann, Annamaria H.; Long, Amanda; Walgren, Richard A.; Gao, Ling; Bell... Journal: British journal of clinical pharmacology Issue: Volume 88:Issue 7(2022) Page Start: 3182 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗